Fiona Bath-Hextall

Fiona Bath-Hextall

Auto-generated profile, based on publicly available information

Fiona Bath-Hextall

Centre for Evidence Based Healthcare, School of Health Sciences, Faculty of Medicine and Health Sciences, The University of Nottingham, Nottingham, U.K.

Research Focus & Metrics

Academic Career Length

28Years (1999-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 January 2012 in British Journal of Dermatology
Verified
Journal Article
Open access
PDF file
ALA. Lomas
A. Lomas
JLJ. Leonardi‐Bee
J. Leonardi‐Bee
FBF. Bath‐Hextall
F. Bath‐Hextall
Background Nonmelanoma skin cancer (NMSC) is the most common cancer affecting white‐skinned individuals and the incidence is increasing worldwide. Objectives This systematic review brings together 75 studies conducted over the past half century to look at geographical variations and trends worldwide in NMSC, and specifically incidence data are compared with recent U.K. cancer registry data. Methods Following the development of a comprehensive search strategy, an assessment tool was adapted to look at the methodological quality of the eligible studies. Results Most of the studies focused on white populations in Europe, the U.S.A. and Australia; however, limited data were available for other skin types in regions such as Africa. Worldwide the incidence for NMSC varies widely with the highest rates in Australia [> 1000/100 000 person‐years for basal cell carcinoma (BCC)] and the lowest rates in parts of Africa (< 1/100 000 person‐years for BCC). The average incidence rates in England were 76·21/100 000 person‐years and 22·65/100 000 person‐years for BCC and squamous cell carcinoma (SCC), respectively, with highest rates in the South‐West of England (121·29/100 000 person‐years for BCC and 33·02/100 000 person‐years for SCC) and lowest rates by far in London (0·24/100 000 person‐years for BCC and 14·98/100 000 person‐years for SCC). The incidence rates in the U.K. appear to be increasing at a greater rate when compared with the rest of Europe. Conclusions NMSC is an increasing problem for health care services worldwide. This review highlights a requirement for prevention studies in this area and the issues surrounding incomplete NMSC registration. Registration standards of NMSC should be improved to the level of other invasive disease.

4 November 2013 in BMJ
Verified
Journal Article
Open access
PDF file
LLLouise Lansbury
Louise Lansbury
FBFiona Bath-Hextall
Fiona Bath-Hextall
WPWilliam Perkins
William Perkins
WSWendy Stanton
Wendy Stanton
JLJ. Leonardi-Bee
J. Leonardi-Bee
Objectives To assess the effects of treatments for non-metastatic invasive squamous cell carcinoma (SCC) of the skin using evidence from observational studies, given the paucity of evidence from randomised controlled trials. Design Systematic review of observational studies. Data sources Medline, Embase, to December 2012. Review methods Observational studies of interventions for primary, non-metastatic, invasive, SCC of the skin that reported recurrence during follow-up, quality of life, initial response to treatment, adverse events, cosmetic appearance, or death from disease. Studies were excluded if data for primary cutaneous SCC was not separable from other data. Data were extracted independently by two reviewers. Meta-analysis was performed where appropriate using a random effects model to estimate the pooled proportion of an event with 95% confidence intervals. Results 118 publications were included, covering seven treatment modalities. Pooled estimates of recurrence of SCCs were lowest after cryotherapy (0.8% (95% confidence interval 0.1% to 2%)) and curettage and electrodesiccation (1.7% (0.5% to 3.4%)), but most treated SCCs were small, low risk lesions. After Mohs micrographic surgery, the pooled estimate of local recurrence during variable follow-up periods from 10 studies was 3.0% (2.2% to 3.9%), which was non-significantly lower than the pooled average local recurrence of 5.4% (2.5% to 9.1%) after standard surgical excision (12 studies), and 6.4% (3.0% to 11.0%) after external radiotherapy (7 studies). After an apparently successful initial response of SCCs to photodynamic therapy, pooled average recurrence of 26.4% (12.3% to 43.7%; 8 studies) was significantly higher than other treatments. Evidence was limited for laser treatment (1 study) and for topical and systemic treatments (mostly single case reports or small non-comparative series with limited follow-up). Conclusions Many observational studies have looked at different treatment modalities for SCC, but the evidence base for the effectiveness of these interventions is poor. Comparison of outcomes after different treatments should be interpreted cautiously owing to biases inherent in the types of study included, and lack of direct comparisons to enable the estimation of relative treatment effect. Further evidence is needed to develop a prognostic model and stratify individuals at high risk of developing SCC, to improve the evidence base for this common cancer and to optimise clinical management. Protocol registration International Prospective Register of Systematic Reviews (PROSPERO) registration number CRD42011001450.

1 September 2015 in JBI Evidence Implementation
Verified
Journal Article
Closed access
APAlan Pearson
Alan Pearson
HWHeath White
Heath White
FBFiona Bath-Hextall
Fiona Bath-Hextall
SSSusan Salmond
Susan Salmond
JAJoao Appstolo
Joao Appstolo
PKPamela Kirkpatrick
Pamela Kirkpatrick
There are an increasing number of published single-method systematic reviews that focus on different types of evidence related to a particular topic. As policy makers and practitioners seek clear directions for decision-making from systematic reviews, it is likely that it will be increasingly difficult for them to identify 'what to do' if they are required to find and understand a plethora of syntheses related to a particular topic.Mixed-methods systematic reviews are designed to address this issue and have the potential to produce systematic reviews of direct relevance to policy makers and practitioners.On the basis of the recommendations of the Joanna Briggs Institute International Mixed Methods Reviews Methodology Group in 2012, the Institute adopted a segregated approach to mixed-methods synthesis as described by Sandelowski et al., which consists of separate syntheses of each component method of the review. Joanna Briggs Institute's mixed-methods synthesis of the findings of the separate syntheses uses a Bayesian approach to translate the findings of the initial quantitative synthesis into qualitative themes and pooling these with the findings of the initial qualitative synthesis.

1 January 2014 in The Lancet Oncology
Verified
Journal Article
Open access
FBFiona Bath-Hextall
Fiona Bath-Hextall
MOMara Ozolins
Mara Ozolins
SASarah J Armstrong
Sarah J Armstrong
GCGraham B Colver
Graham B Colver
WPWilliam Perkins
William Perkins
HWHywel C Williams
Hywel C Williams
Basal-cell carcinoma is the most common form of skin cancer and its incidence is increasing worldwide. We aimed to assess the effectiveness of imiquimod cream versus surgical excision in patients with low-risk basal-cell carcinoma. We did a multicentre, parallel-group, pragmatic, non-inferiority, randomised controlled trial at 12 centres in the UK, in which patients were recruited between June 19, 2003, and Feb 22, 2007, with 3 year follow-up from June 26, 2006, to May 26, 2010. Participants of any age were eligible if they had histologically confirmed primary nodular or superficial basal-cell carcinoma at low-risk sites. We excluded patients with morphoeic or recurrent basal-cell carcinoma and those with Gorlin syndrome. Participants were randomly assigned (1:1) via computer-generated blocked randomisation, stratified by centre and tumour type, to receive either imiquimod 5% cream once daily for 6 weeks (superficial) or 12 weeks (nodular), or surgical excision with a 4 mm margin. The randomisation sequence was concealed from study investigators. Because of the nature of the interventions, masking of participants was not possible and masking of outcome assessors was only partly possible. The trial statistician was masked to allocation until all analyses had been done. The primary outcome was the proportion of participants with clinical success, defined as absence of initial treatment failure or signs of recurrence at 3 years from start of treatment. We used a prespecified non-inferiority margin of a relative risk (RR) of 0.87. Analysis was by a modified intention-to-treat population and per protocol. This study is registered as an International Standard Randomised Controlled Trial (ISRCTN48755084), and with ClinicalTrials.gov, number NCT00066872. 501 participants were randomly assigned to the imiquimod group (n=254) or the surgical excision group (n=247). At year 3, 401 (80%) patients were included in the modified intention-to-treat group. At 3 years, 178 (84%) of 213 participants in the imiquimod group were treated successfully compared with 185 (98%) of 188 participants in the surgery group (RR 0.84, 98% CI 0.78-0.91; p<0.0001). No clear difference was noted between groups in patient-assessed cosmetic outcomes. The most common adverse events were itching (211 patients in the imiquimod group vs 129 in the surgery group) and weeping (160 vs 81). We recorded serious adverse events in 99 (40%) of 249 participants in the imiquimod group and 97 (42%) of 229 in the surgery group had serious adverse events, but none were regarded as related to treatment. 12 (5%) participants in the imiquimod group withdrew because of adverse events compared with four (2%) in the surgery group. Imiquimod was inferior to surgery according to our predefined non-inferiority criterion. Although excisional surgery remains the best treatment for low-risk basal-cell carcinoma, imiquimod cream might still be a useful treatment option for small low-risk superficial or nodular basal-cell carcinoma dependent on factors such as patient preference, size and site of the lesion, and whether the patient has more than one lesion. Cancer Research UK.

5 March 2010 in British Journal of Dermatology
Verified
Journal Article
Closed access
PDF file
BHBath‐ Hextall
Bath‐ Hextall
F.F.J.
F.J.
ABA.J. Birnie
A.J. Birnie
JRJ.C. Ravenscroft
J.C. Ravenscroft
HWH.C. Williams
H.C. Williams

19 July 2007 in International Journal of Cancer
Verified
Journal Article
Closed access
PDF file
FBFiona Bath‐Hextall
Fiona Bath‐Hextall
JLJo Leonardi‐Bee
Jo Leonardi‐Bee
CSChris Smith
Chris Smith
AMAndy Meal
Andy Meal
RHRichard Hubbard
Richard Hubbard